SLGC Stock - SomaLogic, Inc.
Unlock GoAI Insights for SLGC
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|
| Revenue | $97.67M | $81.63M | $55.89M | $32.19M |
| Gross Profit | $54.30M | $48.16M | $33.27M | $-17,533,000 |
| Gross Margin | 55.6% | 59.0% | 59.5% | -54.5% |
| Operating Income | $-175,761,000 | $-73,304,000 | $-34,356,000 | $-50,957,000 |
| Net Income | $-109,157,000 | $-86,302,000 | $-71,353,000 | $-57,002,000 |
| Net Margin | -111.8% | -105.7% | -127.7% | -177.1% |
| EPS | $-0.59 | $-0.63 | $-0.39 | $-0.31 |
SomaLogic, Inc. operates as a protein biomarker discovery and clinical diagnostics company in the United States. It develops slow off-rate modified aptamers (SOMAmers), which are modified nucleic acid-based protein binding reagents that are specific for their cognate protein; and offers proprietary SomaScan services, which provide multiplex protein detection and quantification of protein levels in complex biological samples. The company's SOMAmers/SomaScan technology enables researchers to analyze various types of biological samples for protein biomarker signatures, which can be utilized in drug discovery and development. Its SomaScan's biomarker discoveries help in diagnostic applications in various areas of diseases, including cardiovascular and metabolic disease, nonalcoholic steatohepatitis, wellness, and others. The company also provides SomaSignal research use only and laboratory-developed tests. It serves research and clinical customers with a focus on pharmaceutical and biotechnology companies, and academic research institutions, as well as facilitates drug development, analysis of clinical trials, and new human biology insights by assessing protein-protein and protein-gene networks. The company was incorporated in 1999 and is headquartered in Boulder, Colorado.
Visit WebsiteRating Distribution
Price Targets
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| October 5th 2023 | Jefferies | Downgrade | Hold | $2.3← $3.5 |
| September 25th 2023 | Canaccord Genuity | Downgrade | Hold | $2.5← $5 |
Earnings History & Surprises
SLGCEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q4 2023 | Nov 8, 2023 | $-0.17 | $-0.12 | +29.4% | ✓ BEAT |
Q3 2023 | Aug 14, 2023 | $-0.18 | $-0.13 | +27.8% | ✓ BEAT |
Q2 2023 | May 11, 2023 | $-0.21 | $-0.18 | +14.3% | ✓ BEAT |
Q1 2023 | Mar 28, 2023 | $-0.26 | $-0.26 | 0.0% | = MET |
Q4 2022 | Nov 14, 2022 | $-0.20 | $-0.18 | +10.0% | ✓ BEAT |
Q3 2022 | Aug 15, 2022 | $-0.19 | $-0.13 | +31.6% | ✓ BEAT |
Q2 2022 | May 12, 2022 | $-0.15 | $-0.15 | 0.0% | = MET |
Q1 2022 | Mar 29, 2022 | $-0.12 | $-0.16 | -33.3% | ✗ MISS |
Q4 2021 | Nov 15, 2021 | — | $-0.33 | — | — |
Q4 2021 | Oct 15, 2021 | — | $-0.12 | — | — |
Q2 2021 | May 24, 2021 | — | $-0.05 | — | — |
Q4 2020 | Dec 31, 2020 | — | $-0.05 | — | — |
Q3 2020 | Sep 30, 2020 | — | $-0.04 | — | — |
Frequently Asked Questions about SLGC
What is SLGC's current stock price?
What is the analyst price target for SLGC?
What sector is SomaLogic, Inc. in?
What is SLGC's market cap?
Does SLGC pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to SLGC for comparison